About: SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology
Creator	Kikkert, Marjolein Bárcena, Montserrat Sidorov, Igor Druce, Julian Zevenhoven-Dobbe, Jessika Caly, Leon Snijder, Eric Dalebout, Tim De Vries, Jutte Limpens, Ronald Ogando, Natacha Van Der Meer, Yvonne
source	BioRxiv
abstract	The sudden emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of 2019 from the Chinese province of Hubei and its subsequent pandemic spread highlight the importance of understanding the full molecular details of coronavirus infection and pathogenesis. Here, we compared a variety of replication features of SARS-CoV-2 and SARS-CoV and analysed the cytopathology caused by the two closely related viruses in the commonly used Vero E6 cell line. Compared to SARS-CoV, SARS-CoV-2 generated higher levels of intracellular viral RNA, but strikingly about 50-fold less infectious viral progeny was recovered from the culture medium. Immunofluorescence microscopy of SARS-CoV-2-infected cells established extensive cross-reactivity of antisera previously raised against a variety of nonstructural proteins, membrane and nucleocapsid protein of SARS-CoV. Electron microscopy revealed that the ultrastructural changes induced by the two SARS viruses are very similar and occur within comparable time frames after infection. Furthermore, we determined that the sensitivity of the two viruses to three established inhibitors of coronavirus replication (Remdesivir, Alisporivir and chloroquine) is very similar, but that SARS-CoV-2 infection was substantially more sensitive to pre-treatment of cells with pegylated interferon alpha. An important difference between the two viruses is the fact that - upon passaging in Vero E6 cells - SARS-CoV-2 apparently is under strong selection pressure to acquire adaptive mutations in its spike protein gene. These mutations change or delete a putative ‘furin-like cleavage site’ in the region connecting the S1 and S2 domains and result in a very prominent phenotypic change in plaque assays.
has issue date	2020-04-20(xsd:dateTime)
bibo:doi	10.1101/2020.04.20.049924
has license	biorxiv
sha1sum (hex)	1b3f2d41d8b3ee09175d8e4fd6dcf7660bc9efed
schema:url	https://doi.org/10.1101/2020.04.20.049924
resource representing a document's title	SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology
schema:publication	bioRxiv
resource representing a document's body	covid:1b3f2d41d8b3ee09175d8e4fd6dcf7660bc9efed#body_text
is schema:about of	named entity 'caused' named entity 'coronavirus' named entity 'viral' named entity 'molecular' named entity 'viral' named entity 'sudden' named entity 'viruses' named entity 'Immunofluorescence microscopy' named entity 'SARS-CoV-2' named entity 'ROs' named entity 'protein' named entity 'virus' named entity 'Coronavirus' named entity 'protein' named entity 'hepatitis' named entity 'passaging' named entity 'SARS-CoV' named entity 'HuH7' named entity 'clone' named entity 'phenotype' named entity 'public health' named entity 'viral proteins' named entity 'phenotype' named entity 'subgenomic mRNA' named entity 'PBS' named entity 'EMBL' named entity 'virus' named entity 'assay' named entity 'SARS-CoV-2' named entity 'antisera' named entity 'genome' named entity 'deletions' named entity 'electron microscopy' named entity 'cross-react' named entity 'SARS-CoV-2' named entity 'antisera' named entity 'protein' named entity 'Golgi complex' named entity 'intracellular' named entity 'antisera' named entity 'peptide' named entity 'SARS-CoV-2' named entity 'Hoechst 33258' named entity 'cross-reactivity' named entity 'antisera' named entity 'NGS' named entity 'passaged' named entity 'SARS-CoV-2' named entity 'pegylated interferon' named entity 'endosomes' named entity 'clone' named entity 'SARS-CoV' named entity 'single-nucleotide' named entity 'mutation' named entity 'phenotypic change' named entity 'genome sequence' named entity 'antisera' named entity 'virus replication' named entity 'SARS-CoV' named entity 'infection' named entity 'evolution' named entity 'assay' named entity 'mutation' named entity 'ACE2 receptor' named entity 'antiserum' named entity 'nsp6' named entity 'viral RNA' named entity 'dsRNA' named entity 'antiserum' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'chloroquine' named entity 'NGS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software